long intergenic non-protein coding RNA 1257Genealiases: []
Q-omics provides the consensus-scored LINC01257 profile across patient tissues and cancer cell-line models. LINC01257 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, LINC01257 is differentially expressed in 5, with the highest sampling consensus in THCA. Additionally, LINC01257 RNA expression shows 11,167 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight DLBC, THCA, and THYM as cancer lineages where LINC01257 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01257 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01257 survival associations across molecular data types. LINC01257 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01257 RNA expression–survival associations across cancer types. High LINC01257 expression shows unfavorable associations in DLBC, MESO, UVM, UCEC and LIHC, but favorable associations in UCS. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for LINC01257 RNA expression.
This table summarizes LINC01257 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01257. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01257 shows lower tumor expression in THCA, KICH, KIRC and BRCA and higher tumor expression in LIHC. The THCA box plot shows higher LINC01257 RNA expression in normal versus tumor tissue (log2 FC = −1.448, t-test p < 0.001).
This table shows molecular features associated with LINC01257 in patient tissues and cancer cell lines. In patient samples, LINC01257 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
